Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13454194 | 0.91 | GAA (0.50) | GBA1CYP19A1CCR3ALOX15GRIN2B | |
| SCHEMBL15114430 | 0.84 | GRIN2B (0.44) | GBA1CCR3GRIN2BALDH1A1SIGMAR1 | |
| SCHEMBL4865561 | 0.84 | GBA1 (0.48) | GBA1CYP19A1CCR3GRIN2BSIGMAR1 | |
| SCHEMBL4865573 | 0.84 | GBA1 (0.48) | GBA1CYP19A1CCR3GRIN2BSIGMAR1 | |
| SCHEMBL5136681 | 0.82 | EP300 (0.44) | GBA1CYP19A1ALDH1A1KMT2A | |
| SCHEMBL5136682 | 0.82 | EP300 (0.44) | GBA1CYP19A1ALDH1A1KMT2A | |
| SCHEMBL6261865 | 0.81 | GBA1 (0.46) | GBA1CYP19A1CCR3ALOX15GRIN2B | |
| SCHEMBL11359163 | 0.81 | HDAC8 (0.50) | GBA1CYP19A1CCR3ALOX15MEN1 | |
| SCHEMBL3982415 | 0.81 | NOS3 (0.50) | GBA1CYP19A1CCR3GRIN2BSIGMAR1 | |
| SCHEMBL20005917 | 0.80 | CYP3A4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-114206832-B | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-04 | — | — | CN | disclosed |
| CN-115960750-A | Baeyer-Villiger monooxygenase, mutant and application thereof in preparation of chiral butyrolactone | 华东理工大学 | 2023-04-14 | — | — | CN | disclosed |
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| EP-2172459-B1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | TOKUYAMA CORP (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8404860-B2 | Compound having hydantoin ring and method of producing the same | TOKUYAMA CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20120289705-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | SHIIGI HIROFUMI (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8258313-B2 | Compound having hydantoin ring and method of producing the same | TOKUYAMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| CN-1178911-C | pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative diseases | - | 2004-12-08 | — | — | CN | disclosed |
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004054564-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| CN-1425002-A | Pyrrolidine and piperidine derivatives and their use for treatment of neurodegenerative disorders | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | CN | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
| US-4020171-A | CHEMICAL INTERMEDIATES | SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289705-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | CASP14, CYP8B1, DDT | GBA1 725/4885CYP19A1 314/4885CCR3 2901/4885 |
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | GBA1 960/4885CYP19A1 3832/4885CCR3 2924/4885 |
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | LPAR1, LPAR2, LPAR3 | GBA1 960/4885CYP19A1 3832/4885CCR3 2924/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | GBA1 2575/4885CYP19A1 708/4885CCR3 647/4885 |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | GBA1 1681/4885CYP19A1 3265/4885CCR3 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.